ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [09/17/2025 15:52 PDT] ArriVent BioPharma, Inc. (NASDAQ:avbp), Down By 100% ($18.87) From $18.87 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [09/17/2025 07:19 PDT] avbp Expected to Trade Down Short Term
• [09/11/2025 07:28 PDT] avbp Expected to Trade Down Short Term
• [08/28/2025 07:17 PDT] avbp Expected to Trade Down Short Term
• [08/26/2025 07:26 PDT] avbp Expected to Trade Down Short Term
• [08/25/2025 07:19 PDT] avbp Expected to Trade Up After Bullish Patterns Develop
• [08/22/2025 11:07 PDT] ArriVent BioPharma, Inc. (NASDAQ:avbp), Up By 100% ($18.54) From $18.54 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [08/19/2025 07:16 PDT] avbp Expected to Trade Down Short Term
• [08/11/2025 10:29 PDT] ArriVent BioPharma, Inc. (NASDAQ:avbp), Down By 100% ($19.59) From $19.59 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [08/08/2025 07:08 PDT] avbp Expected to Trade Up After Bullish Patterns Develop
• [08/07/2025 07:14 PDT] avbp Expected to Trade Up After Bullish Patterns Develop
• [07/31/2025 07:28 PDT] avbp Expected to Trade Down Short Term
• [07/21/2025 10:29 PDT] avbp SqueezeTrigger Price is $0.00. There is $0 That Short Sellers Still Need To Cover.